September 8, 2021 7:36am

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with/without the “pump/promote”?

Pre-open indications: SELLs: 2; BUY: 3; Maintain SELL: 1

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

Never leave an investor uninformed!

Dow futures are DOWN -0.01% (-6 points), S&P futures are DOWN -0.02% (-1 point) and NASDAQ futures are DOWN -0.04% (-6 point)


Stock futures were fluctuating and slipping down in early morning trading on Wednesday,

European stocks retreated reflecting cautious trade in global markets amid nervousness over economic growth and a resurgence in Covid cases.

Asia-Pacific stocks were mixed, as data showed Japan’s economy saw 1.9% annualized growth, higher than the initial estimate for a 1.3% rise.


Data Docket: The Labor Department will release its closely watched Job Openings and Labor Turnover Survey. Meanwhile, the Federal Reserve is set to publish its periodic “Beige Book” survey of activity across its 12 districts.

  • Mortgage demand falls to lowest in two months as rates stagnate



The S&P 500 fell -0.3%, the Dow dropped -0.76, while the Nasdaq rose less than +0.1% to eke out a record close., on Tuesday in relatively thin trading following the Labor Day weekend.

One of the catalysts for a sell-off could be the Federal Reserve and the potential for it to pull back an unprecedented monetary stimulus to support the economy throughout the pandemic. <CNBC>


If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:


  1. The Nasdaq closed UP +10.81 points (+0.07%);
  2. the IBB closed down -0.21% and XBI closed down -0.54%;
  3. Sector volume was LOW with 3 of the 10-upside having higher than the 3-month average volume with very LOW volume of 4 of 22-downside having higher than the 3-month average volume;
  4. The CBOE Volatility Index (VVIX: INDEX), Tuesday was up +1.73 points or +10.54% at 18.14;
  5. Tuesday’s percentage (%) of the 10-upside were +0.25% (FATE) to +12.31% (QURE) while the 22-downside -0.24% (BLFS) to -21.43% (BSTG);



  • September, 2 positive and 2 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21 Earnings releases …  … to date:


Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?

Biostage (BSTG) closed down -$0.75 to $2.75 with 6,705 shares traded following Monday’s Holiday and last Friday’s +$0.39 to $3.50 with 980 shares traded, Thursday’s +$0.11 with 14,339 shares traded, Wednesday’s -$0.36 to $3.00 with 22,300 shares traded and last Tuesday’s -$0.44 to $3.36 with 11,564 shares traded following the previous Monday’s +$0.75 to $3.80 with 25,607 shares traded,

The previous week’s Friday’s +$0.45 to $3.05 with 19,982 share traded, Thursday’s +$0.39 with 3,137 shares traded, Wednesday’s +$0.16 with 18,472 shares traded following Tuesday’s +$0.28 with 10,590 shares traded and the former and previous Monday’s +$0.68 to $1.89 with 38,354 shares traded.

Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial?

Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares?  WHERE is the SEC?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.


Pre-open Indications:  who’s lookin’ which way …


BioLife Solutions (BLFS) closed down -$0.13, has NO pre-market indication but, has a 24.4% jump in August and a 52-week change of +141.76%

ReNeuron (RENE.L) closed flat Tuesday following Friday’s up +$4.00 and is bouncing down -$1.82 on Tuesday,


BUY – on declines and possible bounces:

Intellia Therapeutics (NTLA) closed down Tuesday -$13.53 to $163.25 after Friday’s up again +$2.77 to $176.78 after Thursday’s +$9.97, Wednesday’s +$4.51, last Tuesday’s+$6.58 with a negative -$0.21 or -0.13% pre-market indication,

CRISPR Therapeutics (CRSP) closed down again -$1.45 to $120.51 following Friday’s -$5.11 to $121.96 and has a positive +$1.79 or +1.49% pre-market indication,

Editas Medicine (EDIT) closed down again -$1.52 to $66.73 after Friday’s $4.69 and has a negative -$0.33 or -0.49% pre-market indication,


The BOTTOM LINE: Investors will be keeping an eye on sector sentiment on Wednesday after Tuesday bit the dust after markets were closed on Monday for a holiday.

The editing stocks were cheap and ready to be bought…

The setup for stem, cell and gene therapy sector equities is a unique universe and is showing a lot of resilience in the face of some waning economic data and the lack of new clinical date releases.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Investors should take short-term profits to cash-up for coming drifts!

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO) – still trying to access, Pluristem (PSTI) and ReNeuron (RENE.L)

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.